ArticleKidney international reports2025
Uric Acid Trajectories and CKD Progression in the African American Study of Kidney Disease and Hypertension.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Longitudinal serum uric acid trajectories and chronic kidney disease progression.Irish journal of medical science · 2026Article
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- Association Between Time-Averaged Serum Uric Acid and Renal Outcomes in Patients with Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Multicenter Retrospective Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Uric Acid and Chronic Kidney Disease.Kidney medicine · 2026Review
- Dynamic Uric Acid Changes and Outcomes in CKD in the African American Study of Kidney Disease and Hypertension.Kidney international reports · 2025Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
Introduction: Serum uric acid levels increase with progressive kidney disease, and chronic elevations may contribute to chronic kidney disease (CKD) progression. We analyzed data from the African American Study of Kidney Disease and Hypertension (AASK) to examine the hypothesis that individuals with declining serum urate levels during follow-up would experience slower loss of kidney function. Methods: The AASK recruited 1094 African-American individuals with reduced estimated glomerular filtration rate (eGFR) and followed up with them for up to 12 years. The eGFR and defined end-stage kidney disease (ESKD) composite score were used to establish CKD stages. We employed a Cox proportional hazards model to investigate the association between uric acid trajectories and the composite ESKD outcome. Results: Compared with the normo-increasing uric acid group (i.e., those who had the lowest overall serum uric acid levels), the high-stable (hazard ratio [HR] = 2.28, Conclusion: Uric acid trajectories are associated with ESKD incidence in African Americans with CKD. Tracking temporal changes in uric acid improves the assessment of ESKD risk in CKD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.